About NADFaq.com

NADFaq is a reference site for readers trying to understand what the NAD+ literature says, how different precursors compare, and where product or delivery claims run ahead of the evidence. The site synthesizes peer-reviewed research on Nicotinamide Adenine Dinucleotide (NAD+), its precursors (NMN, NR, Nam, NA), mechanisms, delivery routes, and brand-level quality signals into citation-linked, searchable pages.

NADFaq also publishes clear disclosure information alongside its editorial standards. Current commercial practice is documented on conflict of interest. Today the site does not use paid placements, affiliate links, commission-based brand relationships, or sponsored content; if that changes, the disclosure page and affected content will be updated with a date-stamped note.

What we publish

• Reference entities. Precursors, mechanisms, delivery methods, benefits, and brand profiles — structured, factual, citation-linked, and labeled when evidence is limited.
• Research summaries. Plain-language breakdowns of individual peer-reviewed papers with PMID and DOI links to the source.
• Comparison and analysis. Matrices, tables, and evidence grades that put multiple precursors, delivery methods, or studies side by side.
• Commentary. Short-form pieces responding to new research, industry developments, or reader questions — sourced and reviewed before publication.

Why the synthesis exists

The NAD+ conversation is spread across journal articles, supplement sites, podcasts, and forum summaries. NADFaq exists to make that landscape easier to navigate. We bring human trials, mechanistic papers, pharmacokinetic data, and brand quality signals into one place so readers can compare the evidence, see uncertainty, and trace claims back to primary sources. When support is limited to preclinical work, short-term studies, or manufacturer-provided documents, that limitation is stated explicitly.

How the site is built

Published pages follow a documented editorial workflow. Content may appear under a named contributor or the NADFaq editorial team byline, and additional subject-matter review is added where dosing, safety, delivery, or mechanistic claims require it. Publication and review/update metadata are shown where applicable. The editorial standards are documented at editorial policy, and the evidence-grading framework is at methodology.

Editorial corrections, source suggestions, and feedback: editorial@nadfaq.com.